These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 36809883)

  • 1. Oncolytic virus therapy for malignant gliomas: entering the new era.
    Fudaba H; Wakimoto H
    Expert Opin Biol Ther; 2023 Mar; 23(3):269-282. PubMed ID: 36809883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
    Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
    Front Immunol; 2021; 12():721830. PubMed ID: 34675919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.
    Stergiopoulos GM; Concilio SC; Galanis E
    Curr Treat Options Oncol; 2024 Jul; 25(7):952-991. PubMed ID: 38896326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
    Hua L; Wakimoto H
    Expert Opin Biol Ther; 2019 Aug; 19(8):845-854. PubMed ID: 31046478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success.
    Hervás-Corpión I; Alonso MM
    Int Rev Cell Mol Biol; 2023; 379():169-188. PubMed ID: 37541723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving systemic delivery of oncolytic viruses.
    Hill C; Carlisle R
    Expert Opin Drug Deliv; 2019 Jun; 16(6):607-620. PubMed ID: 31144549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
    Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
    Suryawanshi YR; Schulze AJ
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.
    Vazaios K; van Berkum RE; Calkoen FG; van der Lugt J; Hulleman E
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies.
    Shimizu K; Kahramanian A; Jabbar MADA; Turna Demir F; Gokyer D; Uthamacumaran A; Rajan A; Saad MA; Gorham J; Wakimoto H; Martuza RL; Rabkin SD; Hasan T; Wakimoto H
    Cancer Lett; 2023 Sep; 572():216363. PubMed ID: 37619813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune landscape and response to oncolytic virus-based immunotherapy.
    Lin C; Teng W; Tian Y; Li S; Xia N; Huang C
    Front Med; 2024 Jun; 18(3):411-429. PubMed ID: 38453818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
    Barnard Z; Wakimoto H; Zaupa C; Patel AP; Klehm J; Martuza RL; Rabkin SD; Curry WT
    Neurosurgery; 2012 Sep; 71(3):741-8; discussion 748. PubMed ID: 22653387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gospel of malignant Glioma: Oncolytic virus therapy.
    Li J; Meng Q; Zhou X; Zhao H; Wang K; Niu H; Wang Y
    Gene; 2022 Apr; 818():146217. PubMed ID: 35093451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
    Heidbuechel JPW; Engeland CE
    J Hematol Oncol; 2021 Apr; 14(1):63. PubMed ID: 33863363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
    Nguyen HM; Bommareddy PK; Silk AW; Saha D
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
    Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
    Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oncolytic virotherapy in head and neck cancer].
    Runge A; Petersson M; Riechelmann H
    Laryngorhinootologie; 2022 Oct; 101(10):787-796. PubMed ID: 35977557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oncolytic viruses for therapy of malignant glioma].
    Sosnovtceva AO; Grinenko NF; Lipatova AV; Chumakov PM; Chekhonin VP
    Biomed Khim; 2016 May; 62(4):376-90. PubMed ID: 27562991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A viral attack on brain tumors: the potential of oncolytic virus therapy.
    Mokhtarpour K; Akbarzadehmoallemkolaei M; Rezaei N
    J Neurovirol; 2024 Jun; 30(3):229-250. PubMed ID: 38806994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.